An emerging biotechnology company developing first-in-class transformational therapies for rare bleeding disorders faced a pivotal operational challenge: to achieve an on-time database lock (DBL) for a complex, global Phase Ib study in von Willebrand disease (VWD). This point represented a critical prerequisite for a scheduled End of Phase II meeting with the FDA. With sites spanning six countries across four continents and a sponsor-accelerated timeline requiring query resolution three days ahead of the original target date, the program demanded a partner with both rigorous data operations capabilities and strong, established site relationships.
Read the full case study to learn how Worldwide reconciled all protocol deviations and secured Principal Investigator sign-off ahead of schedule, enabling the sponsor to enter Phase III discussions with confidence.
